With fenebrutinib, the company aims to launch a new oral treatment for multiple sclerosis that offers both greater ...
Swiss pharmaceuticals powerhouse Roche announced on Saturday that the company’s experimental multiple sclerosis drug met its primary goal in a late-stage trial in patients with a rare form of the ...
A University of Toronto-led study has identified a possible biomarker linked to multiple sclerosis (MS) disease progression. The findings, validated in both mouse and in humans, could help to identify ...
Merck and Mayo Clinic are partnering to use AI technology and large-scale clinical data to speed drug development in MS and other conditions.
BERLIN, Feb 7 (Reuters) - Swiss pharmaceutical company Roche said on Saturday its experimental multiple sclerosis drug fenebrutinib met the main goal in a late-stage trial in patients with primary ...
Add Yahoo as a preferred source to see more of our stories on Google. The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results